| Jose Reinaldo Soto, | |
|
410 Ave Hostos, Mayaguez, PR 00682-1560 | |
| (787) 652-9200 | |
| Not Available |
| Full Name | Jose Reinaldo Soto |
|---|---|
| Gender | Male |
| Speciality | Student In An Organized Health Care Education/training Program |
| Location | 410 Ave Hostos, Mayaguez, Puerto Rico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962966846 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 14982-I (Puerto Rico) | Secondary |
| 390200000X | Student In An Organized Health Care Education/training Program | 36280-R (Puerto Rico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jose Reinaldo Soto, 10 Calle Jj, Jardines De Arecibo, Arecibo, PR 00612 Ph: (787) 209-9430 | Jose Reinaldo Soto, 410 Ave Hostos, Mayaguez, PR 00682-1560 Ph: (787) 652-9200 |
News Archive
Measuring blood flow in the brain may be an easy, noninvasive way to predict stroke or hemorrhage in children receiving cardiac or respiratory support through a machine called ECMO, according to a new study by researchers at Nationwide Children's Hospital.
Mom always said you need your sleep, and it turns out, she was right. According to a new study published in Science this week from researchers at the Perelman School of Medicine at the University of Pennsylvania, lack of sleep in young fruit flies profoundly diminishes their ability to do one thing they do really, really well - make more flies.
Researchers at UC San Diego and Creighton University have challenged the intake of vitamin D recommended by the National Academy of Sciences Institute of Medicine, stating that their Recommended Dietary Allowance (RDA) for vitamin D underestimates the need by a factor of ten.
Aegera Therapeutics Inc. released today encouraging survival data from the Phase 1 portion of its Phase 1-2 Study of the novel targeted therapeutic, AEG35156, given in combination with sorafenib in patients with advanced hepatocellular carcinoma (primary liver cancer).
Immunomedics, Inc. a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that all 12 applications from the Company were certified by the Internal Revenue Service of the Department of Treasury as qualified investments in accordance with the Qualifying Therapeutic Discovery Project (QTDP) program under section 48D of the Internal Revenue Code. As a result, the Company will receive an aggregate cash award of $2.9 million.
› Verified 7 days ago